Seattle, Washington, September 23, 2026
Variant Bio, a genomics-driven AI drug discovery company, has expanded its multi-year research collaboration and license agreement with Boehringer Ingelheim to include cardiovascular disease target discovery. The expanded collaboration builds on the companies’ existing work in kidney disease and will apply Variant Bio’s AI-powered Inference platform to discover and validate novel, genetically supported therapeutic targets for cardiovascular conditions. Under the expanded agreement, Variant Bio is eligible for an additional upfront payment as well as potential license and milestone payments that could bring the total value of the expanded collaboration to more than $250 million.
AI and Human Genetics Drive Target Discovery
The collaboration will combine Variant Bio’s genomics, artificial intelligence, deep-phenotyping, and multi-omic data capabilities with Boehringer Ingelheim’s established scientific expertise in cardiovascular and renal-metabolic diseases. Variant Bio’s Inference platform is designed to analyze large-scale biological datasets to identify genetic associations that may provide evidence for potential therapeutic targets. The platform combines large language models, machine learning, and statistical genetics to analyze hundreds of billions of data points generated from studies involving diverse populations worldwide. By incorporating human genetic evidence into the target-discovery process, the companies aim to identify biological targets with stronger links to disease mechanisms and human health outcomes. Variant Bio studies populations and individuals with distinctive health-related traits to identify genetic variants that may reveal mechanisms relevant to disease. These discoveries can then be evaluated as potential starting points for drug development programs, although targets identified through the collaboration will still require extensive validation and development before any potential medicines could reach patients.
Collaboration Expands Into Cardiovascular Disease
The cardiovascular expansion builds on an earlier collaboration between Variant Bio and Boehringer Ingelheim focused on kidney disease. The companies are now extending their research relationship into cardiovascular disease, reflecting the close biological and clinical relationship between cardiovascular and kidney disorders. Boehringer said the expanded collaboration is intended to identify genetically supported targets that could potentially open new approaches to treatment. The companies have not disclosed the specific cardiovascular targets or individual disease programs that will be pursued under the expanded agreement. They also have not announced a development timeline for potential drug candidates arising from the research. The immediate focus is therefore on target discovery and validation, an early stage of the pharmaceutical research process in which biological hypotheses are evaluated before potential therapeutic programs advance into preclinical and clinical development.
Advertisement
Agreement Could Exceed $250 Million
Under the terms of the expanded collaboration, Variant Bio will receive an additional upfront payment and is eligible for potential license and milestone payments totaling more than $250 million. The companies have not publicly disclosed the amount of the additional upfront payment or provided a detailed breakdown of potential milestone payments. The financial figure represents potential future payments associated with successful progress under the agreement rather than guaranteed revenue. For Variant Bio, the expanded agreement provides an opportunity to apply its AI-enabled genomic discovery platform to another major therapeutic area while working with Boehringer Ingelheim’s cardiovascular and renal-metabolic research organization. For Boehringer, the collaboration provides access to Variant Bio’s proprietary human genetic and multi-omic datasets and computational capabilities for identifying potential new drug targets.
The expansion also highlights the growing role of AI, human genetics, and multi-omics in pharmaceutical target discovery. Rather than focusing solely on traditional laboratory approaches, the collaboration combines large-scale biological datasets with computational analysis and disease expertise to generate and assess new therapeutic hypotheses. Any targets emerging from the program will require further scientific validation, development, regulatory evaluation, and clinical testing before their potential therapeutic value can be established.
Source: Variant Bio, Boehringer Ingelheim press release
